Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Osteoporosis 9Breast Neoplasms 6Bone Diseases, Metabolic 5Prostatic Neoplasms 4Triple Negative Breast Neoplasms 1Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteoporosis, Postmenopausal 1Lymphoma 1Lung Neoplasms 1Leukemia 1Esophageal Neoplasms 1Dwarfism, Pituitary 1Carcinoma, Squamous Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenocarcinoma 1

Interventions

Carboplatin 345Cisplatin 240Paclitaxel 208Radiotherapy 206Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 146Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 101Etoposide 98Bevacizumab 96Specimen Handling 84Nivolumab 77durvalumab 73Radiosurgery 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 44Biopsy 43Irinotecan 42Radiation 41Topotecan 39Standard of Care 38Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Risedronic Acid × Clear all
NCT03861091 2023-07-27

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

Wake Forest University Health Sciences

Phase 2 Completed
84 enrolled 13 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡